Replies to post #179955 on Biotech Values

[DewDiligence]

GlobeImmune (GBIM) IPOs 1.73M* shares @$10.00:

http://finance.yahoo.com/news/globeimmune-announces-pricing-initial-public-221444372.html

GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of infectious disease and oncology based on its proprietary Tarmogen platform. Tarmogens are believed to activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture.

In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates for the treatment of cancer [#msg-38279175; http://www.fiercebiotech.com/press-releases/globeimmune-and-celgene-corporation-announce-strategic-global-oncology-alliance ].

In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection [#msg-68297508].

*Assuming exercise of underwriter’s option.